Related Experiment Video
Updated: Jul 5, 2026
04:16
Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
QT/QTc prolongation in placebo-treated subjects: a PhRMA collaborative data analysis
Marilyn A Agin1, William S Aronstein, Georg Ferber
1MM&T Associates LLC (Formerly Pfizer, Inc.), Ann Arbor, Michigan 48105, USA. marilyn.agin@sbcglobal.net
Journal of Biopharmaceutical Statistics
|May 13, 2008
Summary
Understanding QT/QTc data variability is crucial for thorough QT/QTc study design and analysis. Retrospective analyses of electrocardiogram (ECG) data from five PhRMA companies informed these insights.
Area of Science:
- Cardiology
- Clinical Pharmacology
- Biostatistics
Background:
- QT/QTc interval variability can impact the interpretation of thorough QT/QTc studies.
- Pharmaceutical companies are actively researching methods to improve the reliability of QT/QTc data.
- Standardized data collection protocols are essential for robust clinical trial outcomes.
Purpose of the Study:
- To analyze the variability of QT/QTc data from placebo and non-drug electrocardiogram (ECG) recordings.
- To inform the design and analysis of future thorough QT/QTc studies.
- To enhance the understanding of factors influencing QT/QTc interval measurements.
Main Methods:
- Retrospective analysis of 12-lead resting ECG data from five controlled studies.
- Inclusion of data from placebo and non-drug conditions.
- QT intervals were measured by central ECG laboratories.
- Key variables affecting QT/QTc variability were controlled during data collection.
Main Results:
- Analysis focused on understanding the sources and extent of QT/QTc variability.
- Data were obtained from studies where QT/QTc interval collection was a primary objective.
- Controlled variables included resting time, food intake, and lead placement consistency.
Conclusions:
- The findings contribute to a better understanding of QT/QTc data variability.
- Insights gained will aid in optimizing the design and analysis of thorough QT/QTc studies.
- Improved methodologies can lead to more reliable drug safety assessments.
Related Concept Videos
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:15Pharmacodynamic Models: Linear Concentration–Effect Model
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...